Percutaneous cryotherapy is recommended for a range of anatomic and tumor treatment options because of its low pain, good ice visualization, and preservation of collagenous tissue architecture.
Cryotherapy has been performed in the liver, prostate, kidney, and breast with good outcomes. [1] [2] [3] [4] In patients in whom the lung tumor is inaccessible through the tracheobronchial tree, and surgical resection is not indicated, oncological treatment of large tumors is often of limited benefit. Therefore, treatment options are severely restricted. 1 Computed tomography (CT)-guided percutaneous cryotherapy of lung malignancy is considered for patients ineligible for surgery, and a metastatic tumor is associated with low procedural morbidity. 5 Cryotherapy causes coagulation necrosis confined to the tissues within the region of probe application, and ice-ball formation occurs as a result of the dehydration caused by the intracellular ice crystals that form at very low temperatures. This leads to protein denaturation and solute toxicity within the cells. 6, 7 The extent and degree of tissue destruction correlate with the size of the ice ball and the temperature within it. The latest generation of cryotherapy machines use the Joule-Thomson effect, in which different gases undergo unique temperature changes when depressurized, according to unique gas coefficients. The properties of argon make it useful for cooling to below −180ºC, whereas helium is ideal for thawing and re-warming. The use of gas allows for rapid transition from freezing to defrosting, which facilitates tighter control, as well as expedition of the procedure. 8 Based on the biological effect of extreme cold, a lethal temperature of approximately −100ºC at the tumor level is required to achieve total destruction of tumors 2 cm or larger in diameter. 9 We performed percutaneous cryotherapy under CT guidance with local anesthesia as a locally curative treatment for unresectable lung tumors. Twenty-three cryotherapy procedures were performed successfully in 19 patients, with tissue proof of unresected primary lung malignancy, recurrent lung malignancy and lung metastasis.
Materials and Methods

Patients
The institutional review board of our hospital approved this retrospective study and informed consent was waived due to the retrospective and anonymous nature of the analysis. A total of 23 pulmonary masses in 19 patients (10 male and 9 female patients; mean age, 58.7 years; age range, 19-77 years) were treated with cryotherapy between October 2007 and September 2009. Five patients had unresectable non-small cell lung cancer, six had non-small cell lung cancer after lobectomy with recurrence, and the remaining eight patients had lung metastasis. The patients were considered ineligible for surgery or had undergone other lung cancer therapies that were unsuccessful. All of the patients met at least one of the following inclusion criteria: (1) single or multiple peripheral lung masses larger than 1 cm but less than 5 cm in diameter, with previous therapies (radiation therapy, chemotherapy, and/or surgery) having failed;
(2) a nonresectable central lung cancer (as determined by means of surgical consultation, according to size, stage or health status); (3) fewer than five metastatic tumors; and (4) a mass or adenopathy involving the mediastinum and/or the pericardium without distant metastasis. The latter was considered as an inclusion criterion only when it was associated with a distant measurable primary lung tumor.
Cryotherapy technique
The location and size of tumors were noted at preoperative evaluation. A tumor was considered a central mass if it abutted any of the mediastinal or hilar structures. Tumor measurements were obtained in two dimensions on CT images, at the level of the tumor's most prominent appearance in the transverse plane. Patients were placed feet first into the CT gantry for better cryoprobe access.
Cryotherapy was performed after administration of local anesthesia by one thoracic surgeon and one radiologist. For sedation, the patients received 50 mg pethidine (Demoral; Roche, Basel, Switzerland) and 5 mg midazolam (Dormicum; Roche, Basel, Switzerland).
A 21-gauge 15-cm needle was inserted into the center of each mass under CT-guidance (Light speed VCT, GE Medical System, Milwaukee, WI, USA), and used as a guide for subsequent insertion of cryoprobes. The cryoprobe used was a PERC24 (Endocare, Irvine, CA, USA), it was 2.4 mm in diameter and it was inserted directly into the J Formos Med Assoc | 2011 • Vol 110 • No 7 patient. The cryosurgical unit, the Cryocare Surgical System (Endocare), offers a "stick" function for fixating a probe's position once it is inserted into the tumor. This maximized accuracy when multiple cryoprobes were placed.
Cryoablation is achieved using high-pressure argon and helium gas for freezing and thawing, respectively, based on the Joule-Thompson principle. Rapid freezing of tissue with a cryoprobe is based on the rapid expansion of argon gas in a sealed probe with a distal uninsulated portion. This process results in rapid cooling to −100ºC within a few seconds. Active thawing of the ice ball is achieved by introducing helium gas into the probes instead of argon gas. The cryoablation procedure we used consisted of two cycles of 10 minutes of freezing and a 5-minute active thaw between the cycles. During freezing, ice ball growth and tumor coverage were monitored at 5-minute intervals by CT scan. For a mass within the lung tissue, a 2.4-mm cryoprobe can generate an ice ball up to 3.7 cm in diameter and up to 5.7 cm along the probe shaft. For this reason, a single cryoprobe was placed for tumors 2 cm or less in diameter. An additional cryoprobe was used for larger tumors to ensure that an adequate freezing margin of 5-10 mm was achieved. After completion of the final freeze in the cryotherapy procedure, the cryoprobes were warmed by helium gas until the temperature was higher than 20ºC. The cryoprobes were then withdrawn.
Post-procedural evaluation
Immediately after the cryoprobes were removed, the patient was placed back into the CT gantry for scanning and measurement of the low-attenuation ice ball formation. All CT scans obtained after the percutaneous cryoablation were acquired within 2-3 minutes of termination of freezing; the visible size of the ice ball remains relatively unchanged during this time. 2,10,11 A repeat CT scan was performed 24 hours after the procedure to evaluate the type and frequency of complications.
Follow-up helical CT scans of patients were performed at 3 months post-procedure. Changes in tumors following cryotherapy were measured using the Response Evaluation Criteria in Solid Tumors (RECIST) protocol, 12, 13 which is based on objective measurements of lesion size before and after treatment. "Complete response" (CR) indicates disappearance of the lesion, "partial response" (PR) is a decrease of at least 30% in the sum of the longest diameter of target lesions, "progressive disease" (PD) is an increase of at least 20% in the sum of the longest diameter of target lesions, and "stable disease" (SD) is neither sufficient shrinkage to qualify for partial response nor a sufficient increase to qualify for progressive disease.
Results
A total of 23 pulmonary masses in 19 patients were treated with cryotherapy. In all cases, cryotherapy was performed percutaneously under CT guidance with local anesthesia without major complications. Complications are listed in Table 1 . The mean hospital stay after treatment was 2.8 days (range, 2-9 days). There were no treatment-related deaths or conversions to surgical intervention.
The responses to cryotherapy, measured using the RECIST protocol, are listed in Table 2 . We observed a CR in two (8.7%) tumors, PR in 11 (47.8%) tumors, SD in five (21.7%) tumors and PD in five (21.7%) tumors, giving a response rate of 56.5% (Figures 1 and 2 ). treatment alternative when other treatments do not yield sufficient local tumor control. 14 The ability to visualize a low-attenuating ice ball as it thoroughly covers a soft tissue tumor mass during the freeze cycles is a potential benefit that is not available with heat-based treatment.
Discussion
Percutaneous cryotherapy of lung masses is technically feasible and may provide an important
Cryotherapy kills cells and ablates tissue by direct cell injury resulting from ice crystal formation and related deleterious effects, as well as vascular stasis caused by microcirculatory failure. As temperatures fall, direct cellular injury occurs as a result of cellular metabolism failure. When the temperature reaches −20ºC, water in the extracellular environment crystallizes into ice, and withdrawal of the water from the system results in a hyperosmotic extracellular environment. Consequently, denaturation and electrolyte imbalances occur. 15, 16 During thawing, ice crystals fuse to form larger crystals, which eventually disrupt the cell membrane, which is another pathway for causing cell injury. Gage and Baust recommend a minimum freezing temperature of −40ºC for at least 3 minutes for complete eradication of the tumor and a minimum of two freeze-thaw cycles. 15, 16 This leads to modification of cryotherapy techniques, in turn leading to improved biochemical and histological outcomes. 17 In our series, the response of the lung masses was evaluated using the RECIST protocol. In the 11 (47.8%) of 23 tumors diagnosed as PR, local recurrence did not occur during more than 6 months of follow-up. In the two (8.7%) of 23 tumors diagnosed as CR, there was no recurrence during 12 months of follow-up; therefore, our series had a response rate of 56.5%. Cryotherapy offers the opportunity to have excellent healing and resistance to infection. The cryogenic lesion is an anesthetic lesion that initially shows minimal surrounding edema or inflammation. 15, 16 Because of this localized effect, cryotherapy is a well-tolerated procedure. These lesions, which have been found to be relatively resistant to infection, show excellent healing, with minimal scar formation and preservation of tissue planes. 15, 16 We achieved our major treatment goals of using local sedation during the procedures and preserving underlying tissue architecture with minimal complications. Because metastatic lung tumors may associate with other latent metastatic lesions in the lung, pulmonary reserve after treatment can be important. Greater pulmonary reserve is expected after cryotherapy, when applied to centrally located tumors than after surgical procedures such as lobectomy, which is usually required for resection of such tumors.
In conclusion, percutaneous CT-guided cryotherapy offers a viable alternative for a nonsurgical lung mass, because it is minimally invasive and uses local anesthesia, with satisfactory local control. It preserves respiratory function and is well tolerated by the patient. The procedure demands careful patient selection and technical expertise to achieve satisfactory cancer control, patient satisfaction, and acceptable quality of life. 
